[144] Phibro Animal Health Corporation SEC Filing
Phibro Animal Health Corporation (PAHC) filed a Form 144 reporting a proposed sale of 264,000 shares of Class A Common Stock through Goldman Sachs & Co. LLC with an approximate aggregate market value of $8,250,000. The filing lists 20,367,574 shares outstanding and an approximate sale date of 08/19/2025 on NASD. The shares were acquired on 04/14/2014 in a private placement from Phibro Animal Health Corporation, and the consideration is reported as an exchange of securities. The filer states there were no securities sold by the selling person in the past three months and includes the standard signature representation that the person does not possess undisclosed material adverse information.
Phibro Animal Health Corporation (PAHC) ha presentato un modulo 144 per segnalare la proposta vendita di 264.000 azioni di Classe A Common Stock tramite Goldman Sachs & Co. LLC, per un valore di mercato complessivo approssimativo di $8.250.000. La comunicazione indica 20.367.574 azioni in circolazione e una data di vendita prevista per il 19/08/2025 su NASD. Le azioni erano state acquistate il 14/04/2014 in un collocamento privato da Phibro Animal Health Corporation, e la controprestazione è riportata come uno scambio di titoli. Il dichiarante afferma che non sono stati venduti titoli dalla persona venditrice negli ultimi tre mesi e include la consueta dichiarazione firmata che la persona non è in possesso di informazioni materiali avverse non divulgate.
Phibro Animal Health Corporation (PAHC) presentó un Formulario 144 notificando la propuesta de venta de 264.000 acciones de Clase A Common Stock a través de Goldman Sachs & Co. LLC, con un valor de mercado aproximado agregado de $8.250.000. La presentación indica 20.367.574 acciones en circulación y una fecha de venta aproximada del 19/08/2025 en NASD. Las acciones fueron adquiridas el 14/04/2014 en una colocación privada por Phibro Animal Health Corporation, y la contraprestación se registra como un intercambio de valores. El declarante afirma que no se vendieron valores por la persona vendedora en los últimos tres meses e incluye la representación firmada estándar de que la persona no posee información material adversa no divulgada.
Phibro Animal Health Corporation (PAHC)� Form 144� 제출하여 Goldman Sachs & Co. LLC� 통해 264,000주의 클래� A 보통� 매각� 제안했음� 보고했으�, � 시장 가치는 � $8,250,000� 추정됩니�. 제출서에� 유통 주식 수가 20,367,574주이� NASD에서� 예상 매각일을 2025-08-19� 기재하고 있습니다. 해당 주식은 2014-04-14� Phibro Animal Health Corporation으로부터의 사모 발행으로 취득되었으며, 대가� 증권 교환으로 보고되어 있습니다. 제출인은 지� 3개월 동안 해당 매도인이 증권� 매각하지 않았음을 밝히� 있으�, 제출 서명에서 해당인이 공개되지 않은 중대� 불리� 정보� 보유하고 있지 않다� 표준 진술� 포함하고 있습니다.
Phibro Animal Health Corporation (PAHC) a déposé un formulaire 144 signalant une proposition de vente de 264 000 actions de catégorie A Common Stock via Goldman Sachs & Co. LLC, pour une valeur de marché totale approximative de 8 250 000 $. Le document indique 20 367 574 actions en circulation et une date de vente approximative au 19/08/2025 sur la NASD. Les actions ont été acquises le 14/04/2014 lors d’un placement privé auprès de Phibro Animal Health Corporation, et la contrepartie est déclarée comme un échange de titres. Le déposant déclare qu’aucun titre n’a été vendu par la personne vendeuse au cours des trois derniers mois et inclut la représentation signée standard selon laquelle la personne ne possède pas d’informations défavorables importantes non divulguées.
Phibro Animal Health Corporation (PAHC) hat ein Formular 144 eingereicht und damit den geplanten Verkauf von 264.000 Aktien der Klasse A Common Stock über Goldman Sachs & Co. LLC gemeldet, mit einem ungefähren Gesamtmarktwert von $8.250.000. In der Meldung werden 20.367.574 ausstehende Aktien angegeben und ein voraussichtliches Verkaufsdatum am 19.08.2025 bei der NASD genannt. Die Aktien wurden am 14.04.2014 in einer Privatplatzierung von Phibro Animal Health Corporation erworben, und die Gegenleistung ist als Tausch von Wertpapieren angegeben. Der Einreichende erklärt, dass in den letzten drei Monaten keine Wertpapiere durch die verkaufende Person veräußert wurden, und fügt die übliche unterschriebene Erklärung bei, dass die Person keine nicht offengelegten wesentlichen nachteiligen Informationen besitzt.
- Complete procedural disclosure including broker, acquisition date, and nature of acquisition
- No sales in prior three months reported, indicating this is a discrete notice rather than frequent disposals
- Transaction routed through a major broker (Goldman Sachs & Co. LLC), supporting orderly execution
- Proposed sale of 264,000 shares equates to approximately 1.30% of outstanding shares based on numbers provided, which may increase supply pressure
- Transaction described as an exchange of securities rather than a cash purchase, adding complexity to the disposition
Insights
TL;DR: Routine Form 144 disclosing an insider sale of 264,000 shares valued at $8.25M; informational but not evidence of company distress.
The filing documents a proposed sale executed through a major broker with clear acquisition history: the shares were obtained in a 2014 private placement and are to be sold via exchange of securities. The size of the sale�264,000 shares against 20,367,574 outstanding—represents approximately 1.30% of outstanding shares based on the numbers provided. There were no reported sales in the prior three months, which supports this being a discrete planned transaction rather than a series of recent disposals. The disclosure is procedurally complete for a Rule 144 notice and provides necessary timelines and broker details.
TL;DR: Standard compliance filing under Rule 144 showing an insider-originated sale; disclosure meets form requirements.
The notice includes required issuer and transaction details, acquisition source (private placement from the issuer) and the method of payment (exchange of securities). The filer affirms no material nonpublic information, and the absence of other sales in the past three months is explicitly stated. From a governance perspective, the filing appears procedurally appropriate and transparent; it does not by itself indicate compliance issues or governance changes.
Phibro Animal Health Corporation (PAHC) ha presentato un modulo 144 per segnalare la proposta vendita di 264.000 azioni di Classe A Common Stock tramite Goldman Sachs & Co. LLC, per un valore di mercato complessivo approssimativo di $8.250.000. La comunicazione indica 20.367.574 azioni in circolazione e una data di vendita prevista per il 19/08/2025 su NASD. Le azioni erano state acquistate il 14/04/2014 in un collocamento privato da Phibro Animal Health Corporation, e la controprestazione è riportata come uno scambio di titoli. Il dichiarante afferma che non sono stati venduti titoli dalla persona venditrice negli ultimi tre mesi e include la consueta dichiarazione firmata che la persona non è in possesso di informazioni materiali avverse non divulgate.
Phibro Animal Health Corporation (PAHC) presentó un Formulario 144 notificando la propuesta de venta de 264.000 acciones de Clase A Common Stock a través de Goldman Sachs & Co. LLC, con un valor de mercado aproximado agregado de $8.250.000. La presentación indica 20.367.574 acciones en circulación y una fecha de venta aproximada del 19/08/2025 en NASD. Las acciones fueron adquiridas el 14/04/2014 en una colocación privada por Phibro Animal Health Corporation, y la contraprestación se registra como un intercambio de valores. El declarante afirma que no se vendieron valores por la persona vendedora en los últimos tres meses e incluye la representación firmada estándar de que la persona no posee información material adversa no divulgada.
Phibro Animal Health Corporation (PAHC)� Form 144� 제출하여 Goldman Sachs & Co. LLC� 통해 264,000주의 클래� A 보통� 매각� 제안했음� 보고했으�, � 시장 가치는 � $8,250,000� 추정됩니�. 제출서에� 유통 주식 수가 20,367,574주이� NASD에서� 예상 매각일을 2025-08-19� 기재하고 있습니다. 해당 주식은 2014-04-14� Phibro Animal Health Corporation으로부터의 사모 발행으로 취득되었으며, 대가� 증권 교환으로 보고되어 있습니다. 제출인은 지� 3개월 동안 해당 매도인이 증권� 매각하지 않았음을 밝히� 있으�, 제출 서명에서 해당인이 공개되지 않은 중대� 불리� 정보� 보유하고 있지 않다� 표준 진술� 포함하고 있습니다.
Phibro Animal Health Corporation (PAHC) a déposé un formulaire 144 signalant une proposition de vente de 264 000 actions de catégorie A Common Stock via Goldman Sachs & Co. LLC, pour une valeur de marché totale approximative de 8 250 000 $. Le document indique 20 367 574 actions en circulation et une date de vente approximative au 19/08/2025 sur la NASD. Les actions ont été acquises le 14/04/2014 lors d’un placement privé auprès de Phibro Animal Health Corporation, et la contrepartie est déclarée comme un échange de titres. Le déposant déclare qu’aucun titre n’a été vendu par la personne vendeuse au cours des trois derniers mois et inclut la représentation signée standard selon laquelle la personne ne possède pas d’informations défavorables importantes non divulguées.
Phibro Animal Health Corporation (PAHC) hat ein Formular 144 eingereicht und damit den geplanten Verkauf von 264.000 Aktien der Klasse A Common Stock über Goldman Sachs & Co. LLC gemeldet, mit einem ungefähren Gesamtmarktwert von $8.250.000. In der Meldung werden 20.367.574 ausstehende Aktien angegeben und ein voraussichtliches Verkaufsdatum am 19.08.2025 bei der NASD genannt. Die Aktien wurden am 14.04.2014 in einer Privatplatzierung von Phibro Animal Health Corporation erworben, und die Gegenleistung ist als Tausch von Wertpapieren angegeben. Der Einreichende erklärt, dass in den letzten drei Monaten keine Wertpapiere durch die verkaufende Person veräußert wurden, und fügt die übliche unterschriebene Erklärung bei, dass die Person keine nicht offengelegten wesentlichen nachteiligen Informationen besitzt.